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Pontocerebellar hypoplasia type 6 (PCH6) is a rare infantile-onset progressive encephalopathy 21 
caused by biallelic mutations in RARS2 that encodes the mitochondrial arginine-tRNA synthetase 22 
enzyme (mtArgRS). The clinical presentation overlaps that of PEHO syndrome (Progressive 23 
Encephalopathy with oedema, Hypsarrhythmia and Optic atrophy). The proband presented with 24 
severe intellectual disability, epilepsy with varying seizure types, optic atrophy, axial hypotonia, 25 
acquired microcephaly, dysmorphic features and progressive cerebral and cerebellar atrophy and 26 
delayed myelination on MRI. The presentation had resemblance to PEHO syndrome but 27 
sequencing of ZNHIT3 did not identify pathogenic variants. Subsequent whole genome sequencing 28 
revealed novel compound heterozygous variants in RARS2, a missense variant affecting a highly 29 
conserved amino acid and a frameshift variant with consequent degradation of the transcript 30 
resulting in decreased mtArgRS protein level confirming the diagnosis of PCH6. Features 31 
distinguishing the proband’s phenotype from PEHO syndrome were later appearance of hypotonia 32 
and elevated lactate levels in blood and cerebrospinal fluid. On MRI the proband presented with 33 
more severe supratentorial atrophy and lesser degree of abnormal myelination than PEHO 34 
syndrome patients. The study highlights the challenges in clinical diagnosis of patients with 35 




Pontocerebellar hypoplasia type 6, RARS2, PEHO syndrome, progressive cerebellar and cerebral  40 
atrophy  41 





Pontocerebellar hypoplasia (PCH) is a group of neurodegenerative disorders with autosomal 43 
recessive inheritance. Up to date 11 different subtypes have been described, with 17 causative 44 
genes identified (van Dijk et al., 2018). Most of the subtypes are characterized by prenatal or 45 
neonatal onset, global developmental delay and intellectual disability, microcephaly, hypoplasia 46 
and variable atrophy of cerebellar cortex and/or brainstem. The specific neurological symptoms 47 
and the severity of symptoms and brain loss vary between the subtypes (van Dijk et al., 2018). 48 
Pontocerebellar hypoplasia type 6 (PCH6; MIM 611523) is a rare form of PCH first described in 49 
2007 in three patients of a consanguineous Sephardic Jewish family (Edvardson et al., 2007). Since 50 
then, altogether 32 patients in 18 families have been reported in the literature (for a detailed 51 
summary of the patients and phenotypes, see Supplementary Table; Edvardson et al., 2007; Rankin 52 
et al., 2010; Namavar et al., 2011; Glamuzina et al., 2012; Cassandrini et al., 2013; Kastrissianakis 53 
et al., 2013; Joseph et al., 2014; Li et al., 2015; Lax et al., 2015; Nishri et al., 2016; Alkhateeb et al., 54 
2016; Ngoh et al., 2016; van Dijk et al., 2017; Luhl et al., 2016; Zhang et al., 2018). Most PCH6 55 
patients present with neonatal onset, hypotonia, microcephaly, seizures, severe intellectual 56 
disability with lack of developmental milestones and progressive atrophy of cerebral cortex, 57 
cerebellum and pons. The majority show a respiratory chain enzyme deficiency and elevated 58 
lactate levels in blood or cerebrospinal fluid (CSF). Indeed, PCH6 may be distinguished from the 59 
other PCH subtypes, which are highly variable clinically and neuroradiologically, by the presence of 60 
elevated lactate concentration (van Dijk et al., 2018). 61 
PCH6 is caused by biallelic mutations in RARS2, a nuclear gene that encodes the mitochondrial 62 
arginine-tRNA synthetase enzyme (mtArgRS) (Edvardson et al., 2007). Aminoacyl-tRNA synthetases 63 
play a crucial role in protein translation as they catalyze the specific attachment of an amino acid 64 




(aminoacylation) to its cognate tRNA. MtArgRS participates in the synthesis of all 13 mitochondrial-65 
encoded proteins by charging of mitochondrial tRNA-Arg, thus being an integral part of 66 
mitochondrial protein translation machinery, participating in generation of complexes of oxidative 67 
phosphorylation system, except complex II, which has a fully nuclear origin (Ibba and Soll, 2000). 68 
PCH6 shows clinically some resemblance to PEHO syndrome (Progressive Encephalopathy with 69 
oedema, Hypsarrhythmia and Optic atrophy; MIM 260565), characterized by neonatal hypotonia, 70 
profound psychomotor retardation, infantile spasms with hypsarrhythmia and atrophy of optic 71 
disks (Salonen et al., 1991). Patients present with typical dysmorphic features, such as narrow 72 
forehead, epicanthic folds, short nose and open mouth, and edema of the face and limbs (Somer, 73 
1993). Neuroimaging findings include demyelination and progressive atrophy of the cerebellar 74 
cortex, brainstem and optic nerves. In the cerebellum, the inner granular layer is nearly totally 75 
absent and Purkinje cells are deformed and disaligned (Haltia and Somer, 1993). 76 
PEHO syndrome is inherited autosomal recessively and was recently shown to be caused in Finnish 77 
patients by a homozygous missense mutation c.92C>T; p.Leu31Ser in ZNHIT3, a gene encoding zinc 78 
finger HIT domain-containing protein 3 (Anttonen et al., 2017). PEHO syndrome is enriched in the 79 
Finnish population with an estimated incidence of 1:74 000 (Somer, 1993) and approximately 40 80 
diagnosed patients. In other populations it is very rare, with less than 25 reported patients (Field 81 
et al., 2003; Caraballo et al., 2011; Alfadhel et al., 2011) and only one patient with compound 82 
heterozygous mutations in ZNHIT3 reported so far (Öunap et al., 2019). In the literature, patients 83 
with symptoms closely resembling PEHO syndrome are more commonly reported. The clinical 84 
presentation of patients with PEHO-like features, like those with PCH, is similar to that of PEHO 85 
syndrome, but optic atrophy and typical neuroradiologic findings are usually absent or there is no 86 
progression (Field et al., 2003; Longman et al., 2003; Chitty et al., 1996). Several genes underlying 87 




phenotypes resembling PEHO have been described (Rankin et al., 2010; Anttonen et al., 2015; 88 
Gawlinski et al., 2016; Langlois et al., 2016; Nahorski et al., 2016; Flex et al., 2016; Miyake et al., 89 
2016; Zollo et al., 2017; Chitre et al., 2018).  90 
We report a patient with the initial presenting features suggestive of PEHO syndrome with typical 91 
dysmorphic features, epileptic spasms, optic atrophy and severe hypotonia, but in whom whole 92 
genome sequencing revealed novel compound heterozygous mutations in RARS2.  93 




Materials and methods 94 
Patient and samples 95 
The proband was clinically examined by B.C. in Antwerp and was referred to molecular genetic 96 
analyses in Helsinki. DNA extracted from peripheral blood was obtained from the proband and 97 
both parents. Primary fibroblast cultures from the proband were available for analyses of the gene 98 
product.  99 
An institutional review board at the Helsinki University Central Hospital approved the study. A 100 
written informed consent was obtained from the parents. 101 
 102 
Sequencing of ZNHIT3 103 
The five coding exons of ZNHIT3 (NM_004773.3) were Sanger sequenced from genomic DNA of 104 
the proband (primer sequences available upon request). Exon 1 covering the c.8C>T, p.Ser3Leu 105 
variant was also sequenced in the parents. 106 
 107 
Whole genome sequencing 108 
Library preparation for the genomic DNA sample was performed using KAPA Library Preparation 109 
Kit. The sample was sequenced in three lanes of an Illumina HiSeq2500 instrument with one lane 110 
having paired-end 250-bp reads and two lanes paired-end 10-bp reads. Sequence read alignment 111 
to human reference genome (GRCh37) and variant calling (Li et al., 2009) was done as described 112 
earlier with minor modifications (Sulonen et al., 2011). Called variants were annotated using 113 
ANNOVAR (Wang et al., 2010) and filtered using in-house scripts. DELLY (Rausch et al. 2012), which 114 
assesses split-read alignments and paired-end read information to detect structural variants was 115 
used to identify any copy number changes overlapping with the ZNHIT3 locus. Sanger sequencing 116 




was performed from genomic DNA of the patient and the parents to validate the variants 117 
identified by whole genome sequencing and to test segregation of the variants in the family. 118 
Primer sequences are available upon request.  119 
 120 
Sequencing of patient cDNA 121 
Patient fibroblasts were harvested, total RNA extracted (RNeasy plus mini kit, QIAGEN) and 122 
complementary DNA (cDNA) prepared (iScript cDNA synthesis kit, BioRad). Polymerase chain 123 
reaction was performed using primers (sequences available upon request) binding to exons 8 and 124 
14 of RARS2 and the resulting 600-bp product covering the positions of the mutations in exons 10 125 
and 11 was sequenced using standard protocols.  126 
 127 
Western blot analysis 128 
Protein extracts for the detection of mtArgRS, COXII or GAPDH were prepared by lysing fibroblasts 129 
in RIPA buffer (Cell Signaling Technology) containing protease inhibitors (Halt, Thermo Fisher 130 
Scientific). After 10 min incubation on ice the samples were centrifuged at 14 000 g for 10 min (+4 131 
⁰C). Proteins were separated by SDS-PAGE and transferred onto membranes. After blocking with 132 
5% milk in 0.1% TBS–Tween 20, the membranes were incubated with the corresponding primary 133 
antibodies: rabbit anti-human mtArgRS (1:1000, Biorbyt, orb374171), rabbit anti-human COXII 134 
(1:500, GeneTex, GTX62145) or rabbit anti-human GAPDH (Cell Signaling Technology, 14C10). 135 
Reactive bands were detected using horseradish peroxidase-conjugated secondary antibodies 136 
(goat anti-rabbit or goat anti-mouse, 1:10 000, Life Technologies). Blots were imaged using the ECL 137 
western blotting substrate (Thermo Fisher Scientific) and Chemidoc XRS+ Molecular Imager (Bio-138 
Rad). Quantification of the band intensities was performed with the Image Lab Software (Bio-Rad). 139 





Northern blot and aminoacylation assay 141 
Total RNA was extracted from cultured fibroblasts using Trizol reagent (Thermo Fisher scientific) 142 
according to the manufacturer’s instructions. To preserve the aminoacylation state the final RNA 143 
pellet was re-suspended in 10mM NaOAc at pH 5.0. To investigate the aminoacylation status of mt-144 
tRNAs, 4μg of RNA was separated on long (16cm length) 6.5% polyacrylamide gel (19:1 145 
acrylamide:bis-acrylamide) containing 8M urea in 0.1 NaOAc, pH 5.0. The fully deacylated tRNA 146 
(dAc) was obtained by incubation of the control RNA at 75°C (pH 9.0) for 15 min. To determine mt-147 
tRNAArg steady-state levels the samples were run on 10cm gel. Northern hybridization was 148 
performed with ϒ-32P labeled oligonucleotide probes: 5’-GAGTCGAAATCATTCGTTTTG-3’ for the 149 
mt-tRNAArg and 5’- GTGGCTGATTTGCGTTCAGT-3’ for the mt-tRNAAla. Radioactive signal was 150 
detected by PhosphorImager plate using Typhoon scanner and quantified with the ImageQuant 151 
v5.0 software (GE Healthcare).  152 





Clinical description 154 
The essential clinical features in our patient are summarized in Supplementary Table. The patient 155 
was the first child of non-consanguineous Belgian parents. Family history was unremarkable. He 156 
was born at term after an uneventful pregnancy. Birth weight was 3.150 kg (-1 SD), length 50 cm (-157 
1 SD) and head circumference 35 cm (-0.5 SD). After birth slight hypothermia occurred, leading to 158 
one day neonatal care, but otherwise physical examination was normal. Very early psychomotor 159 
milestones were reported normal, but at the age of 2 to 3 months lack of social interaction, late 160 
visual contact and mild hypotonia were noted. No further developmental milestones were 161 
reached, he had no speech and showed no real social contact. The patient had no dysmorphic 162 
signs at birth, but later presented with bitemporal narrowing, high palate, open mouth, full 163 
cheeks, a tented upper lip (Fig. 1A) as well as mild edema of hands (Fig. 1B) and feet. Eye 164 
examination showed no visual contact and a pale papilla on both eyes later progressing to optic 165 
atrophy. Due to feeding difficulties the child was tube fed. An acquired microcephaly was noted 166 
with occipitofrontal circumference (OFC) of 43 cm (-3.3 SD) at the age of 1 year and 46 cm (-3.7 167 
SD) at the age of 3 years. At the last clinical follow-up with 9 years of age, he presented as a 168 
bedridden child with profound intellectual disability, axial hypotonia, spastic quadriplegia and 169 
significant seizure burden.  170 
First convulsions were witnessed at the age of 6 weeks with lateralized clonic movements of the 171 
face, followed by diminished consciousness and eye deviation to one side as well as bilateral clonic 172 
movements of the body. It is unclear from the history whether these seizures were already 173 
present from birth. Convulsions evolved into therapy-resistant epilepsy with varying seizure types: 174 
complex focal seizures (with and without diminished consciousness) with myoclonic jerks and 175 
laughing, rhythmic clonic movements of one or both limbs and long-lasting eye deviations with 176 




nystagmus. The patient suffered from daily seizures several times a day with isolated myoclonic 177 
spams and clusters in between.  178 
EEG studies at the age of one to 3 months showed normal background activity without any 179 
epileptic activity. Multifocal epileptic activity was seen from the age of 4 months and high voltage 180 
slow background activity from the age of 5 months. The EEG did show some signs of 181 
hypsarrhythmia and could, because lack of total desynchronization, be described as a modified 182 
hypsarrhythmia.  The last EEG recording, taken one day before the patient died, demonstrated a 183 
picture of status epilepticus with continuous multifocal epileptic activity. 184 
Magnetic resonance imaging (MRI) was performed at the ages of 4.5 months and 7 years. At 4.5 185 
months (Fig. 1C,D), it showed severe cerebral atrophy, destruction of the thalami, and delayed 186 
myelination, whereas the cerebellum appeared normal in size. At 7 years (Fig. 1E-G), the 187 
cerebellar atrophy was prominent, and microcephaly masked some of the cerebral atrophy. The 188 
pons was normal, and the myelination had reached almost a normal appearance. 189 
Thorough metabolic investigations were unremarkable, with the exception of an intermittently 190 
raised serum lactate up to 5.3 mmol/l (0.5-2 mmol/l) and an elevated lactate level in the CSF, up to 191 
2.8 mmol/l (<2.5 mmol/l). No abnormalities were seen in the muscle biopsy.  192 
Prior genetic investigations including karyotype and microarray came out normal and 193 
mitochondrial DNA mutations were excluded. 194 
The patient died at the age of nearly 12 years due to a respiratory infection. 195 
 196 
Molecular findings: RARS2 mutations and their consequence 197 
Given that the patient presented with symptoms overlapping with those reported in PEHO 198 
syndrome, his DNA was first Sanger sequenced to identify variants in the coding regions and splice 199 




sites of ZNHIT3. A rare heterozygous c.8C>T, p.Ser3Leu (NM_004773.3) missense variant was 200 
identified, but the patient did not have other ZNHIT3 coding sequence variants. To identify any 201 
non-coding variants in ZNHIT3 locus, the patient was whole genome sequenced. Analysis for rare 202 
sequence variants in intronic or UTR regions of ZNHIT3, or up- or downstream to ZNHIT3 did not 203 
identify a second variant. No copy number changes overlapping with the ZNHIT3 locus was 204 
identified. 205 
Analysis of the whole genome data was then expanded to all protein coding regions of the 206 
genome and splice sites. Whole genome sequence data was produced with mean sequencing 207 
coverage of 24.48x, and 98.2%, 95.7% and 74.2% of the genome was covered at least 5x, 10x and 208 
20x, respectively. Analysis of the coding regions from the genome sequence data focused on rare 209 
heterozygous and potentially biallelic variants in established disease genes. Analysis of rare 210 
heterozygous variants did not yield any likely candidates explaining the patient’s disease. Analysis 211 
of rare biallelic variants revealed two heterozygous variants in RARS2 (NM_020320.3; Fig. 2A and 212 
B; https://databases.lovd.nl/shared/individuals/00234052), a one-bp deletion in exon 10 causing a 213 
frameshift and premature termination of translation 16 codons downstream (c.795delA, 214 
p.Glu265Aspfs*16) and a missense variant, c.961C>T, p.Leu321Phe, in exon 11. There is one 215 
heterozygous carrier for the c.961C>T, p.Leu321Phe variant in the gnomAD (Lek et al., 2016) 216 
database (v. 2.0; allele frequency 0.000004), whereas the frameshift variant is absent from the 217 
database. The leucine at position 321, located in the catalytic domain of RARS2, is highly 218 
conserved (Fig. 2B). In silico tools SIFT, PolyPhen-2 and MutationTaster predict the c.961C>T, 219 
p.Leu321Phe substitution as deleterious. Sanger sequencing confirmed compound heterozygosity 220 
of the two mutations in the patient: the c.795delA frameshift mutation was inherited from the 221 
mother and the c.961C>T missense mutation from the father (Fig. 2A).  222 
The consequence of the RARS2 variants was studied on mRNA level in skin fibroblasts of the 223 




patient. The frameshift variant in exon 10 resulting in a premature termination codon is predicted 224 
to be subjected to nonsense-mediated mRNA decay (NMD) and degradation of the transcript 225 
derived from the maternal allele. Indeed, sequencing of RARS2 cDNA revealed that at position 226 
c.961 only the paternal C>T variant was present (Fig. 2C). Western blot analysis of patient 227 
fibroblasts revealed that the mtArgRS protein level was reduced to about 50 % of control level (Fig. 228 
3A). Northern blot analysis of total RNA from fibroblasts suggested that the steady-state level of 229 
mitochondrial tRNAArg when compared to mitochondrial tRNAAla may be decreased in patient 230 
fibroblasts (Fig. 3B). In patient and control fibroblasts, aminoacylation analysis showed the 231 
presence of only aminoacylated mt-tRNAArg, whereas deacylated mt-tRNAArg was not detected (Fig. 232 
3C). This finding is in agreement with the previous observation (Edvardson et al., 2007), suggesting 233 
that in cultured human fibroblasts uncharged mt-tRNAArg is not stable.   234 





We describe a patient compound heterozygous for two novel pathogenic variants in RARS2, the 236 
gene associated with PCH6. The high conservation of the affected Leu321, the predicted 237 
deleteriousness of the Leu321Phe substitution combined with degradation of the transcript 238 
derived from the allele with the frameshift variant strongly suggest that these variants are the 239 
underlying cause for PCH6 in the patient.  240 
The role of RARS2 in pontocerebellar hypoplasia is not fully understood with no clear genotype-241 
phenotype correlations. It is though likely that the severity of the disease is dependent of the 242 
amount of remaining aminoacylation activity (Konovalova and Tyynismaa, 2013). mtArgRS has a 243 
fundamental function in mitochondrial protein synthesis, so total loss-of-function mutations are 244 
likely to be lethal. Compatible with this notion, mice homozygous for a knock-out allele of Rars2 245 
are embryonic lethal (International Mouse Phenotyping Consortium; 246 
http://www.mousephenotype.org/data/genes/MGI:1923596#section-associations). Considering 247 
the markedly reduced expression from the frameshift allele, the missense mutant allele is likely to 248 
retain some mtArgRS activity in our patient. It has been suggested that due to the leaky nature of 249 
the mutations, small amounts of protein synthesis is possible in most tissues, but in high energy 250 
demanding cells, such as neurons, the reduced aminoacylation is not sufficient thus causing the 251 
symptoms of the disease (Edvardson et al., 2007). Low enzyme activity affects the development of 252 
the central nervous system already in utero as demonstrated by abnormal brain MRI findings in 253 
the neonatal period (e.g. Edvardson et al., 2007; Joseph et al., 2014; Lax et al., 2015). It is also 254 
possible that the reduced aminoacylation of tRNA-Arg has bigger effect on specific neuronal types 255 
that causes the alterations in brain typical for PCH6. There is also evidence of particular uncharged 256 
tRNAs and amino acids working as potential signaling molecules (Dong et al., 2000; Wolfson et al., 257 
2016). Mitochondrial tRNA synthetases may also have non-canonical functions, similarly to their 258 




cytosolic counterparts, in addition to their housekeeping function in protein synthesis, and these 259 
may contribute to the pathomechanisms. For example, mtArgRS was recently found to have a 260 
specific sub-mitochondrial localization in the membrane, which suggests that it also could have 261 
alternative functions (Gonzáles-Serrano et al., 2018). Regardless of the reason, this high tissue 262 
specificity makes functional studies of the disease mechanism challenging. 263 
Including the present patient, 33 patients with PCH6 in 19 families have been described 264 
(Supplementary Table). An overview of the key clinical features in the patients is presented in Table 265 
1. Most patients were normal at birth but presented with variable symptoms at early age (hours to 266 
9 months). First presenting features included hypotonia in 15/33 patients and seizures in 16/33 267 
patients. Other early symptoms were poor feeding, lethargy and apneic episodes. All patients were 268 
reported to have global developmental delay and the majority presented seizures, the onset 269 
varying from 9 hours to several months. Most seizures were intractable myoclonic or tonic-clonic 270 
seizures, either focal, or multifocal or generalized. Other common features in the patients include 271 
progressive microcephaly, atrophy of cerebellum and cerebrum, as well as elevated lactate levels 272 
in blood or CSF. Notably, atrophy of pons was reported to be present in only 12 out of the 25 273 
patients with reported MRI findings, indicating that pons can be normal in PCH6 (Nishri et al., 274 
2016). The phenotype in our patient is similar to that of previously published patients, and 275 
presents with all features listed in Table 1, except atrophy of the pons. Of note, as in at least three 276 
published patients (Ngoh et al., 2016; Zhang et al., 2018; Luhl et al., 2016), the serum lactate levels 277 
in our patient were intermittently raised.  278 
Compatible with a previous report (Rankin et al., 2010), the initial clinical features in our patient 279 
including severe intellectual disability, epilepsy, optic atrophy, hypotonia, acquired microcephaly, 280 
mild edema of hands and feet, and dysmorphic features pointed to PEHO syndrome. Although the 281 
dysmorphic features raised the suspicion of the PEHO syndrome, they may, however, be non-282 




specific, as many of the dysmorphic facial features are associated with developing microcephaly, 283 
extreme floppiness, and edema (Somer, 1993). Contrary to findings in our patient, patients with 284 
PEHO syndrome do not show elevated lactate levels in blood or CSF and usually present with 285 
neonatal hypotonia (Anttonen et al., 2017). Importantly, the MRI findings in our patient (Fig. 1C-G) 286 
were not typical for PEHO syndrome. The supratentorial atrophy was more severe than in a typical 287 
PEHO patient. Moreover, the myelination was not delayed to the degree seen in PEHO patients. 288 
Characteristic MRI findings including progressive cerebellar atrophy and dysmyelination are 289 
essential diagnostic criteria for PEHO syndrome (Anttonen et al., 2017).  These typical findings are 290 
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Figure Titles and Legends 304 
Figure 1. Phenotypic features in the patient. 305 
A) Facial features of the patient at 7 years of age. Note the open mouth, full cheeks, a tented 306 
upper lip and bitemporal narrowing. B) The hand shows edema. C) In a sagittal T1-weighted cranial 307 
magnetic resonance image at the age of 4.5 months cerebellum (arrowhead) and pons (arrow) 308 
appear normal in size. D) T2-weighted axial image at 4.5 months shows cerebral atrophy. 309 
E & F) T2-weighted images of the patient at 7 years of age show microcephaly and widespread 310 
cerebral atrophy as well as severe cerebellar atrophy (arrowhead in E) with widened cerebellar 311 
sulci (F). The pons (arrow in E) as well as the myelination appear normal. G) T2-axial slices at 7 312 
years also show atrophy and signal increase of the thalami (open arrowheads). 313 
 314 
Figure 2. Two novel PCH6-associated mutations in the RARS2 gene. 315 
A) Sanger sequencing chromatograms of the proband’s (P) and the parents’ genomic DNA showing 316 
the c.795delA variant inherited from the mother (M) and the c.961C>T variant inherited from the 317 
father (F). Positions of variants are indicated with arrowheads. B) A schematic picture of the exon-318 
intron structure of RARS2 and the domain structure of the encoded protein (modified from 319 
Gonzáles-Serrano et al., 2018) showing the locations of the identified mutations and high 320 
conservation of the leucine at position 321 affected by the missense substitution. C) Sanger 321 
sequencing chromatograms of the proband’s cDNA showing only the paternal c.961C>T variant 322 
(arrowhead) in exon 11 suggesting that the transcript derived from the maternal allele is 323 
degraded.   11F denotes forward orientation sequence and 11R reverse orientation 324 
 325 
Figure 3. Western blot, northern blot and aminoacylation analysis of the patient fibroblasts. 326 




A) Steady-state level of mtArgRS protein in patient (P) and control fibroblasts (C1, C2) detected by 327 
Western blot. Quantification of the Western blot analysis is shown in the right panel. GAPDH was 328 
detected as protein loading control. Data are presented as mean ± SD. B) Northern blot analysis of 329 
mt-tRNAArg levels in patient (P) and control (C1, C2) fibroblasts. Quantification of the northern blot 330 
analysis is shown in the lower panel. Mitochondrial tRNAAla was detected as a loading control.  331 
C) Aminoacylation assay of mt-tRNAArg in control (C1, C2) and patient (P) fibroblasts. Mitochondrial 332 
tRNAAla was detected as a loading control. dAC denotes the fully deacylated control tRNA. 333 
Experiments in B and C were carried out only once.  334 


















Epileptic seizures 24/24  
Microcephaly 20/27  
MRI findings   
      Atrophy of cerebellum 22/25  
      Atrophy of pons 12/25  
      Atrophy of cerebrum 18/25  
Elevated lactate level in blood or CSF 19/23  
Reduced respiratory chain enzyme activity 10/19  
Feeding difficulties 17/18  




CSF – cerebrospinal fluid 338 
 339 
a The features are variably reported in the patients.  340 
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